Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases
6.3 Neurodegenerative disorders Recent research indicates that GLP-1 receptor agonists are potentially advantageous for neurodegenerative disorders (Table 2), especially in light of the recognized association between diabetes and dementia
Retatrutide is a nextgeneration investigational peptide designed to act on three metabolic hormone receptors at oncethe GLP1, GIP, and glucagon receptorsmaking it a triple agonist. In research settings, it has been explored for its potential to influence appetite, energy use, and bodyweightrelated endpoints
The bigger concern often comes after the excitement
It seems like everyone is suddenly talking about Ozempic and the class of medications called GLP-1 agonists. Are they really a weight loss miracle
Peripheral and central immune system crosstalk in Alzheimer diseasea research prospectus